Small Molecules for Precision Medicine

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.

Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need.

Our prioritized clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader in precision medicine.  These drug candidates include:


Tivantinib is an oral selective inhibitor of the MET receptor tyrosine kinase, currently in pivotal Phase 3 trials in second line hepatocellular carcinoma selecting patients for the biomarker-defined MET-high patient population. Learn more»

ARQ 087

ARQ 087 is an oral multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, currently in Phase 2 clinical trial for the treatment of intrahepatic cholangiocarcinoma with FGFR2 fusions. Learn more »

ARQ 092

ARQ 092 is an oral selective and potent pan-AKT inhibitor that inhibits both wild-type and mutant AKT1, currently in development for oncology indications and rare diseases:

ARQ 761

ARQ 761 is an intravenously administered analogue of β-Lapachone that targets patients with elevated levels of NQO1; a Phase 2 trial is about to be launched by our collaborator, the University of Texas Southwestern Medical Center, in pancreatic cancer patients with elevated levels of NQO1. Learn more »

ARQ 751

ARQ 751 is an investigational, orally available, selective, next generation pan-AKT inhibitor that potently inhibits AKT1, 2 and 3 isoforms.               Learn more »

With five internally discovered drugs in multiple biomarker guided clinical trials and an enriched proprietary kinase library from which to select additional drug candidates, ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy.

ArQule is led by a senior management team with significant clinical and commercial expertise that provides the leadership required to optimize its opportunities for success in a rapidly changing and highly competitive field.

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300